P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension
Bibliographic record
Abstract
BACKGROUND: Ozanimod is a potent, selective, sphingosine-1-phosphate receptor subtype 1 (S1P1) modulator that has demonstrated safety and efficacy in patients with moderate-to-severe ulcerative colitis (UC) in the randomized, placebo-controlled, phase 2 TOUCHSTONE study (NCT01647516). This analysis presents data from the extension period of TOUCHSTONE, with ≥4 years of follow-up. METHODS: Patients in TOUCHSTONE received placebo or ozanimod (0.5 mg or 1 mg daily) during the 8-week induction and 24-week maintenance periods and could enter the optional open label extension (OLE) with ozanimod 1 mg/day if they were nonresponders at the end of the induction period, lost response during the maintenance period, or completed the maintenance period. Eligible patients entered the OLE between May 2013; March 2015. In 2019, the OLE was ended and all active patients who consented rolled over to a phase 3 program. During the OLE, patients were followed for safety and efficacy at weeks 4, 8, 12, and 12-week intervals thereafter. Partial Mayo score (pMS, comprised of stool frequency, rectal bleeding, and physician’s global assessment subscores) was assessed at all visits. Endoscopy was performed approximately annually in patient subsets, mainly at OLE weeks 56 and 104 per protocol amendments; total Mayo score (tMS, including pMS subscores plus endoscopy), endoscopic improvement (endoscopic subscore of ≤1), and histologic remission (Geboes score 1). Biomarkers of disease activity were assessed (C-reactive protein [CRP], all visits; fecal calprotectin [FCP], OLE week 8, end of study). RESULTS: Of 170 patients entering the OLE, 123 (72%), 102 (60%), 84 (49%), and 71 (42%) completed OLE weeks 56, 104, 152, and 200, respectively. Using non-responder imputation (NRI) for missing data, pMS clinical response and remission rates at week 56 were 71% and 55%, and 41% and 37%, respectively, at week 200. tMS clinical response and remission rates (observed case analysis) were 83% and 40%, respectively, at week 56, and 82% and 41% at week 104. Observed pMS decreased substantially over time, plateauing at 1. Treatment-emergent adverse events (TEAEs) were UC flare (4%), anemia (1%), and ischemic stroke (1%); no serious TEAEs of cardiac arrhythmias or macular edema were reported. CONCLUSION: Data from the TOUCHSTONE OLE demonstrate durable efficacy by clinical, endoscopic, histologic, and biomarker measures with ozanimod 1 mg/day. No new safety risks were identified with ≥4 years of follow-up.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".